These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

668 related articles for article (PubMed ID: 32749941)

  • 21. Confirmation of ProMisE: A simple, genomics-based clinical classifier for endometrial cancer.
    Talhouk A; McConechy MK; Leung S; Yang W; Lum A; Senz J; Boyd N; Pike J; Anglesio M; Kwon JS; Karnezis AN; Huntsman DG; Gilks CB; McAlpine JN
    Cancer; 2017 Mar; 123(5):802-813. PubMed ID: 28061006
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The clinicopathological characteristics of POLE-mutated/ultramutated endometrial carcinoma and prognostic value of POLE status: a meta-analysis based on 49 articles incorporating 12,120 patients.
    Wu Q; Zhang N; Xie X
    BMC Cancer; 2022 Nov; 22(1):1157. PubMed ID: 36357827
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Incorporation of molecular characteristics into endometrial cancer management.
    Vermij L; Smit V; Nout R; Bosse T
    Histopathology; 2020 Jan; 76(1):52-63. PubMed ID: 31846532
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation of the 2021 molecular ESGO/ESTRO/ESP risk groups in endometrial cancer.
    Imboden S; Nastic D; Ghaderi M; Rydberg F; Siegenthaler F; Mueller MD; Rau TT; Epstein E; Carlson JW
    Gynecol Oncol; 2021 Aug; 162(2):394-400. PubMed ID: 34127276
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical factors as prognostic variables among molecular subgroups of endometrial cancer.
    Kolehmainen A; Pasanen A; Tuomi T; Koivisto-Korander R; Bützow R; Loukovaara M
    PLoS One; 2020; 15(11):e0242733. PubMed ID: 33232359
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Risk stratification and molecular heterogeneity of endometrial cancer and expression profile of TIM-3: A retrospective cohort study.
    Zhang Y; Yang R; Xu C; Zhang Y; Deng M; Wu D; Tang F; Liu X; Han Y; Zhan Y; Miao J
    Gynecol Oncol; 2023 Mar; 170():210-220. PubMed ID: 36709662
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The influence of molecular classification in the selection of postoperative adjuvant therapy in endometrial carcinoma].
    Yan XS; Li M; Liang HM; Guo HY; Wu Y; He HJ; Zhang K; Li H
    Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(32):2500-2505. PubMed ID: 36008320
    [No Abstract]   [Full Text] [Related]  

  • 28. TCGA molecular classification in endometriosis-associated ovarian carcinomas: Novel data on clear cell carcinoma.
    Similä-Maarala J; Soovares P; Pasanen A; Ahvenainen T; Vahteristo P; Bützow R; Lassus H
    Gynecol Oncol; 2022 Jun; 165(3):577-584. PubMed ID: 35370008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of Molecular Classification on Treatment Paradigms in Uterine Cancers.
    Cosgrove CM; Barrington D; Backes FJ
    Curr Oncol Rep; 2021 May; 23(7):75. PubMed ID: 33937919
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Interpretation of somatic POLE mutations in endometrial carcinoma.
    León-Castillo A; Britton H; McConechy MK; McAlpine JN; Nout R; Kommoss S; Brucker SY; Carlson JW; Epstein E; Rau TT; Bosse T; Church DN; Gilks CB
    J Pathol; 2020 Mar; 250(3):323-335. PubMed ID: 31829442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mismatch repair protein and MLH1 methylation status as predictors of response to adjuvant therapy in endometrial cancer.
    Loukovaara M; Pasanen A; Bützow R
    Cancer Med; 2021 Feb; 10(3):1034-1042. PubMed ID: 33449452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular profile-based recommendations for postoperative adjuvant therapy in early endometrial cancer with high-intermediate or intermediate risk: a Chinese randomized phase III trial (PROBEAT).
    Li Y; Zhu C; Xie H; Chen Y; Lv W; Xie X; Wang X
    J Gynecol Oncol; 2023 Mar; 34(2):e37. PubMed ID: 36659832
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prognostic value of the TCGA molecular classification in uterine carcinosarcoma.
    Travaglino A; Raffone A; Raimondo D; Arciuolo D; Angelico G; Valente M; Scaglione G; D'alessandris N; Casadio P; Inzani F; Mollo A; Santoro A; Seracchioli R; Franco Zannoni G
    Int J Gynaecol Obstet; 2022 Jul; 158(1):13-20. PubMed ID: 34536971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Molecular subtype stratified outcomes according to adjuvant therapy in endometrial cancer.
    Jamieson A; Huvila J; Leung S; Chiu D; Thompson EF; Lum A; Kinloch M; Helpman L; Salvador S; Vicus D; Kean S; Samouelian V; Grondin K; Irving J; Offman S; Parra-Herran C; Lau S; Scott S; Plante M; McConechy MK; Huntsman DG; Talhouk A; Kommoss S; Gilks CB; McAlpine JN
    Gynecol Oncol; 2023 Mar; 170():282-289. PubMed ID: 36753816
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Time to first recurrence, pattern of recurrence, and survival after recurrence in endometrial cancer according to the molecular classification.
    Siegenthaler F; Lindemann K; Epstein E; Rau TT; Nastic D; Ghaderi M; Rydberg F; Mueller MD; Carlson J; Imboden S
    Gynecol Oncol; 2022 May; 165(2):230-238. PubMed ID: 35277281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. p53 immunohistochemistry is an accurate surrogate for TP53 mutational analysis in endometrial carcinoma biopsies.
    Singh N; Piskorz AM; Bosse T; Jimenez-Linan M; Rous B; Brenton JD; Gilks CB; Köbel M
    J Pathol; 2020 Mar; 250(3):336-345. PubMed ID: 31829441
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.
    Santoro A; Angelico G; Travaglino A; Raffone A; Arciuolo D; D'Alessandris N; Inzani F; Zannoni GF
    Gynecol Oncol; 2021 May; 161(2):629-635. PubMed ID: 33712277
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic significance of POLE proofreading mutations in endometrial cancer.
    Church DN; Stelloo E; Nout RA; Valtcheva N; Depreeuw J; ter Haar N; Noske A; Amant F; Tomlinson IP; Wild PJ; Lambrechts D; Jürgenliemk-Schulz IM; Jobsen JJ; Smit VT; Creutzberg CL; Bosse T
    J Natl Cancer Inst; 2015 Jan; 107(1):402. PubMed ID: 25505230
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adjuvant chemoradiotherapy versus radiotherapy alone for women with high-risk endometrial cancer (PORTEC-3): final results of an international, open-label, multicentre, randomised, phase 3 trial.
    de Boer SM; Powell ME; Mileshkin L; Katsaros D; Bessette P; Haie-Meder C; Ottevanger PB; Ledermann JA; Khaw P; Colombo A; Fyles A; Baron MH; Jürgenliemk-Schulz IM; Kitchener HC; Nijman HW; Wilson G; Brooks S; Carinelli S; Provencher D; Hanzen C; Lutgens LCHW; Smit VTHBM; Singh N; Do V; D'Amico R; Nout RA; Feeney A; Verhoeven-Adema KW; Putter H; Creutzberg CL;
    Lancet Oncol; 2018 Mar; 19(3):295-309. PubMed ID: 29449189
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mismatch repair deficiency as a predictive marker for response to adjuvant radiotherapy in endometrial cancer.
    Reijnen C; Küsters-Vandevelde HVN; Prinsen CF; Massuger LFAG; Snijders MPML; Kommoss S; Brucker SY; Kwon JS; McAlpine JN; Pijnenborg JMA
    Gynecol Oncol; 2019 Jul; 154(1):124-130. PubMed ID: 31103324
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 34.